Gapping up
In reaction to earnings/guidance:
- APPS +17.3%, GOOS +16%, HIMX +11.8%, ALGN +10.7% (also announces commercial availability of Invisalign G8), EBAY +10.1% (also increases dividend by 13%, expands share repurchase plan by $4 bln), MWA +9.4%, QNST +7.8%, SIMO +7.6%, KLIC +7.3%, MXL +7.1%, HI +6.9%, MDP +6.4%, PYPL +6.1% (also co discusses allowing customers to use their crypto balance as a funding source), IAC +5.7%, INOV +5%, SNA +4.9%, ALGT +4.6%, ECHO +4.5%, TBI +4.3%, PH +3.8%, LSPD +3.3%, MET +3%, YUM +2.9%, CTVA +2.7%, BDX +2.6%, BKE +2.4%, ABC +2.3%, VSAT +2.2%, TSE +2.1%, TPR +1.9%, CCMP +1.8%, PLUS +1.7%, SU +1.6%, DGX +1.6%, MSGN +1.6%, TAK +1.5%, THG +1.4%, CSGS +1.4%, YUMC +1.3%, HSY +1.3%, BEP +1.1%, AGCO +1.1%, MAA +1%, CHNG +1%, TW +1%
Other news:
- AVXL +90.5% (Blackrock increases passive stake to 5.5% (prior 5.2%))
- THTX +81.8% (FDA has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy)
- VGAC +13.9% (VG Acquisition Corp. enters into merger agreement with 23andMe)
- CRVS +13.1% (announces that it has initiated a Phase 3 clinical trial of CPI-006 for the treatment of hospitalized patients with COVID-19)
- XL +7% (announces strategic partnership with Curbtender for development of all-electric and plug-in hybrid refuse trucks)
- PHUN +5.5% (files for $100 mln mixed securities shelf offering)
- ORMP +3% (stock offering)
- PME +2.5% (Pingtan Marine Enterprise signs a Cooperation Agreement in the field of live broadcast e-commerce)
- CVAC +2.3% (expands lead RNA cancer program phase 1 trial in advanced melanoma)
- KPTI +2.2% (partner receives regulatory approval for XPOVIO in Israel)
- SDC +1.9% (in sympathy with strong earnings from ALGN)
- AAPL +1.8% (close to finalizing a deal with Hyundai-Kia to make Apple Car autonomous EV, citing sources, according to CNBC)
- AZUL +1.5% (reports Q4 revenue growth)
- IMMR +1.4% (files for $250 mln mixed securities shelf offering)
- CDXC +1.4% (reports that new study results finds nutritional protocol including nicotinamide riboside reduces liver fat and improves liver function)
- QDEL +1% (opens new manufacturing facility)
Analyst comments:
- OCGN +13.5% (upgraded to Buy from Neutral at H.C. Wainwright)
- ALGT +4.6% (upgraded to Buy from Hold at Deutsche Bank)
- MTCH +3.3% (upgraded to Overweight from Neutral at JP Morgan)
- APAM +2.8% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- FEYE +2.7% (upgraded to Buy from Neutral at BofA Securities)
- CDW +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)